[Clinical studies on tobramycin by intravenous drip infusion for Pseudomonas aeruginosa infection in chronic respiratory diseases (author's transl)].

Tobramycin (TOB) was administrated by intravenous drip infusion for 1 hour, to 15 patients with intractable chronic respiratory tract infections due to P. aeruginosa, and the following results were obtained. 1. Criteria of clinical effects We have made new criteria for the evaluation of the therapeutic effects on respiratory tract infections (Tables 1, 2). Clinical items were divided into 4 grades and radiographic ones into 6 to 11 grades. Each item was separately scored as followed; excellent was scored as 1 point when 3 or more grade upward-shifts were seen after treatment, good as 2 points in case of 2 grade upward-shifts, fair as 3 points in case of 1 grade upward-shift, unchanged as 4 points in case of no shift, impairment as 5 points in case of downward-shift. The integrated evaluation of the items was made according to the average points for the evaluated items; overall excellent was 1.9 or less, overall good 2.0 to 2.9, overall fair 3.0 to 3.5 and overall poor as 3.6 or more. 2. Clinical effects Overall clinical effects were evaluated as good in 7 cases, fair in 4 and poor in 4 out of 15 patients, and rate of good score was 46.7%. According to the dosage groups, rate of good score was 50% in the dose of 60 mg three times a day, 0% in the dose of 90 mg twice a day and 62.5% in the dose of 120 mg twice a day. Eradication rate of P. aeruginosa was 33.3%. Neither adverse side effects nor abnormal laboratory findings were observed.